110 likes | 238 Vues
This report by Susanne Ludgate, presented at the 11th GHTF Conference in Washington D.C. (October 2007), outlines the role of global stakeholders in harmonizing clinical evidence requirements for regulatory acceptance. Key components include the establishment of uniform definitions and guidance across regulatory bodies like the FDA, Health Canada, and others. The report discusses the status and progress of clinical evaluations, the critical data sources, and the anticipated challenges, highlighting the ongoing efforts towards implementing these harmonized standards in clinical investigations across various countries.
E N D
11th GHTF CONFERENCEWASHINGTON DCOCTOBER 2007SG5: CLINICAL EVALUATIONSTATUS REPORTSUSANNE LUDGATE Name MHRA Date 2007
ROLE to work towards convergence of clinical evidence requirements to yield common data for the purpose of acceptance by global regulators • harmonised definitions • harmonised guidance • MOU ISO TC 194
MEMBERSHIP • Commission, COCIR, EDMA, EUCOMED • FDA, AdvaMed, NEMA • Health Canada, MEDEC • TGA, MIAA • MHLW, JFMDA
DOCUMENT FINALISED • clinical investigation • clinical data • clinical evaluation • clinical evidence • process data generation, clinical evaluation clinical evidence: key definitions and concepts (N1R8)
DOCUMENT FINALISED • when, why, process • general principles (scope, how performed, who performs) • sources of data (experience, literature, investigation) • appraisal • analysis • clinical evaluation report clinical evaluation (N2/R8)
IMPLEMENTATION PLANS • Japan: intending to implement • EU: already implemented • Australia: progress in implementation • Canada: intentions incorporated in Regulations • USA: law and definitions compatible
DOCUMENT IN PROGRESS IVD Subgroup (SG1) Chair: Nancy Shadeed “…..responsible for working on a harmonised format for pre-market submissions…..”
DOCUMENT IN PROGRESS • when undertaken/ general principles • general principles need • general principles design • specific details design • ethical considerations clinical investigation
DOCUMENT IN PROGRESS • what is it • when needed • type of study • plan, objectives post-market clinical follow-up studies
OBSTACLES • impact local law and regulations • layers of review • time to feedback • lack mechanism to facilitate similar documents
THE FUTURE….. following completion of stated documents….. No further plans!!